These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 21284532)
1. Setting up TRAPS. Pettersson T; Kantonen J; Matikainen S; Repo H Ann Med; 2012 Mar; 44(2):109-18. PubMed ID: 21284532 [TBL] [Abstract][Full Text] [Related]
2. Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): state of the art and future perspectives. Cantarini L; Lucherini OM; Muscari I; Frediani B; Galeazzi M; Brizi MG; Simonini G; Cimaz R Autoimmun Rev; 2012 Nov; 12(1):38-43. PubMed ID: 22884554 [TBL] [Abstract][Full Text] [Related]
3. Tumor necrosis factor receptor-associated periodic fever syndrome in a 58-year-old man: caution not to discount TRAPS as a diagnosis in older patients. Sinožić D; Toplak N; Milotić I J Clin Rheumatol; 2011 Sep; 17(6):325-8. PubMed ID: 21869706 [TBL] [Abstract][Full Text] [Related]
4. Recurrent migratory angioedema as cutaneous manifestation in a familiar case of TRAPS: dramatic response to Anakinra. Cattalini M; Meini A; Monari P; Gualdi G; Arisi M; Pelucchi F; Bolognini S; Gattorno M; Calzavara-Pinton PG; Plebani A Dermatol Online J; 2013 Nov; 19(11):20405. PubMed ID: 24314780 [TBL] [Abstract][Full Text] [Related]
5. Revisiting TNF Receptor-Associated Periodic Syndrome (TRAPS): Current Perspectives. Cudrici C; Deuitch N; Aksentijevich I Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32380704 [TBL] [Abstract][Full Text] [Related]
6. [Tumor necrosis receptor associated periodic syndrome (TRAPS): State of the art]. Georgin-Lavialle S; Kone-Paut I; Delaleu J; Sarrabay G; Grateau G; Touitou I; Hentgen V Rev Med Interne; 2018 Apr; 39(4):256-264. PubMed ID: 29525418 [TBL] [Abstract][Full Text] [Related]
7. "Periodic fever" without fever: two cases of non-febrile TRAPS with mutations in the TNFRSF1A gene presenting with episodes of inflammation or monosymptomatic amyloidosis. Kallinich T; Haffner D; Rudolph B; Schindler R; Canaan-Kühl S; Keitzer R; Burmester GR; Roesen-Wolff A; Roesler J Ann Rheum Dis; 2006 Jul; 65(7):958-60. PubMed ID: 16308343 [TBL] [Abstract][Full Text] [Related]
10. A novel mutation (T61I) in the gene encoding tumour necrosis factor receptor superfamily 1A (TNFRSF1A) in a Japanese patient with tumour necrosis factor receptor-associated periodic syndrome (TRAPS) associated with systemic lupus erythematosus. Ida H; Kawasaki E; Miyashita T; Tanaka F; Kamachi M; Izumi Y; Huang M; Tamai M; Origuchi T; Kawakami A; Migita K; Motomura M; Yoshimura T; Eguchi K Rheumatology (Oxford); 2004 Oct; 43(10):1292-9. PubMed ID: 15280569 [TBL] [Abstract][Full Text] [Related]
11. Autosomal recessive transmission of TRAPS in a family with a novel TNFRSF1A mutation. Wong KK; Jackson J; Whidborne R; Mallon D; Bennetts B; D'Orsogna LJ Scand J Rheumatol; 2015 May; 44(3):255-6. PubMed ID: 25744939 [No Abstract] [Full Text] [Related]
12. Different presentations in patients with tumor necrosis factor receptor-associated periodic syndrome mutations: report of two cases. Celebi-Tayfur A; Bilginer Y; Finetti M; Gattorno M; Ozen S Turk J Pediatr; 2013; 55(1):78-81. PubMed ID: 23692837 [TBL] [Abstract][Full Text] [Related]
13. Failure of sustained response to etanercept and refractoriness to anakinra in patients with T50M TNF-receptor-associated periodic syndrome. Quillinan N; Mannion G; Mohammad A; Coughlan R; Dickie LJ; McDermott MF; McGonagle D Ann Rheum Dis; 2011 Sep; 70(9):1692-3. PubMed ID: 21378401 [No Abstract] [Full Text] [Related]
14. On-demand treatment with anakinra: a treatment option for selected TRAPS patients. Grimwood C; Despert V; Jeru I; Hentgen V Rheumatology (Oxford); 2015 Sep; 54(9):1749-51. PubMed ID: 26078218 [No Abstract] [Full Text] [Related]
15. TRAPS mutations in Akagi T; Hiramatsu-Asano S; Ikeda K; Hirano H; Tsuji S; Yahagi A; Iseki M; Matsuyama M; Mak TW; Nakano K; Ishihara K; Morita Y; Mukai T Front Immunol; 2022; 13():926175. PubMed ID: 35936010 [TBL] [Abstract][Full Text] [Related]
16. [Progress in classification and treatment for TNF receptor-associated periodic syndrome]. Tsukamoto H; Ueda N; Horiuchi T Nihon Rinsho Meneki Gakkai Kaishi; 2011; 34(5):361-8. PubMed ID: 22041423 [TBL] [Abstract][Full Text] [Related]
18. Advances in the diagnosis and treatment of tumor necrosis factor receptor-associated periodic syndrome. Aguado-Gil L; Irarrazaval-Armendáriz I; Pretel-Irazabal M Actas Dermosifiliogr; 2013 Sep; 104(7):617-22. PubMed ID: 23891452 [TBL] [Abstract][Full Text] [Related]
19. The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: clinical manifestations and long-term follow-up. Cantarini L; Rigante D; Merlini G; Vitale A; Caso F; Lucherini OM; Sfriso P; Frediani B; Punzi L; Galeazzi M; Cimaz R; Obici L Semin Arthritis Rheum; 2014 Jun; 43(6):818-23. PubMed ID: 24393624 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of anakinra in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) complicated by severe renal failure: a report after long-term follow-up and review of the literature. Gentileschi S; Rigante D; Vitale A; Sota J; Frediani B; Galeazzi M; Cantarini L Clin Rheumatol; 2017 Jul; 36(7):1687-1690. PubMed ID: 28536823 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]